Norstella：2024年肿瘤学的下一波浪潮：七大突破性创新研究报告（英文版）

He notes that while chemotherapy still forms the backbone of many treatment regimens, the promise of ADCs lies in their ability to “leverage the advances of antibody technologies to make cytotoxic agents more effective and safer for patients.” Roche, leading the market in 2023 with over $3 billion in sales from Kadcyla and Polivy, is expected to be overtaken by Daiichi Sankyo by 2028. The latter predicted to generate close to $10 billion from Enhertu and datapotamab deruxtecan3. The competiti